Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review ...
Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p13,765.50. The company has a one-year high of p13,388.00 and a one-year low of p9,461.00.
Shares of AstraZeneca PLC AZN rose 2.18% to £109.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.83% to 8,319.69.
Despite higher quarterly revenue, AstraZeneca's earnings per share are lower. NVO Revenue (Quarterly) data by YCharts Also, with Novo Nordisk's high-flying GLP-1 medicines -- and AstraZeneca's ...
NICE has recommended extended funding on the NHS for AstraZeneca’s high potassium drug Lokelma in final draft guidance. In a decision applying to England and Wales the cost-effectiveness body ...
LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision ...
AstraZeneca has announced a substantial $3.5 billion investment in US operations through 2026. This investment aims to create over 1,000 high-skilled jobs across its American facilities. The expansion ...
LONDON (Reuters) - AstraZeneca said on Tuesday it had voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision drug for ...
AstraZeneca is a company with a turbulent history ... oncology and local and general anaesthesia. These are still high on the list of AZ’s core focus today. In August 2000, Nexium (esomeprazole ...
GIMP 3.0 revamps the interface for high-resolution screens Keeps projects compatible with older versions Extensive testing ensures a bug-free GIMP 3.0 After two decades of anticipation ...